Gilead inks deals with 3 Indian cos for low-cost HIV drug

New Delhi: Drug major Gilead Sciences has signed deals with three Indian firms, including Ranbaxy Laboratories, to collaborate on promoting access to low-cost generic versions of its HIV medicine emtricitabine in developing countries.

Under the new agreements with Indian companies -- Ranbaxy, Strides Arcolab and Mylan Laboratories, "Gilead will provide a technology and funding to assist reduce overall manufacturing costs," a company statement said today.

The partnership will help the Indian firms to manufacture high volumes of emtricitabine and tenofovir disoproxil fumarate (TDF)-based HIV medicines, establishing sustainable price parity to these alternative regimens, the world`s biggest maker of HIV drugs said.

"Ongoing collaboration (with Indian companies) will be critical for furthering access to affordable, high-quality, first-line HIV treatment for developing countries," Gilead`s Chairman and CEO John C Martin said.

More than 2.7 million patients living with HIV in developing countries are currently receiving a TDF-containing regimen, a medicine innovated by Gilead and subsequently licenced to Indian generic partners to increase global access to effective treatment, he said.

Ranbaxy Laboratories CEO and Managing Director, Arun Sawhney said: "This association with Gilead will enable us to offer quality affordable medicines for the treatment of HIV/AIDS in developing countries".

California-based Gilead sells emtricitabine under the brand name Emtriva.


By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link